10-Year Study Confirms High Success of HER2+ Breast Cancer Therapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.Researchers involved with the phase 2 NIMBUS trial observed no new safety concerns with the combination.